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Introduction
Cancer is the second leading cause of death in 
developing countries (Ferlay et al., 2010; Keyghobadi 
et al., 2015; Koohi et al., 2015; ). In Iran located in 
epidemiologic transition, cancer is the third cause of death 
after coronary heart disease and accidents (Mousavi et al., 
2009; Khajehkazemi et al., 2013). Incidence of cancer is 
increasing in developing countries as a result of population 
aging and cancer- associated lifestyle such as smoking, 
physical inactivity, obesity, stress and so on. It is expected 
to increase the number of new cases of cancer from 10 
million per year in 2000 to 15 in 2020, and nearly 60% 
of them occurred in developing countries (Parkin et al., 
2005).
Lung cancer is a major health problem and the leading 
cause of cancer deaths worldwide (Ming et al., 2014) so 
scholars pay more and more attention to its diagnosis, 
treatment and prognosis. According to the International 
Agency for Research on Cancer (IARC) GLOBOCAN 
World Cancer Report, lung cancer affects more than 1 
million people a year and certainly stands to be a leading 
cause of cancer mortality worldwide (Jemal et al., 2011). 
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Abstract
 Background: Lung cancer is one of the most common cancers in the world and a major cause of death from 
cancer. One of the important indicators to compare the prevalence and incidence of the disease is a change in the 
trend. The aim of this study was to investigate the changes in the incidence of lung cancer in Iran. Materials and 
Methods: This study was conducted based on existing data obtained from a national registry of cancer cases and 
the Disease Management Center of Ministry of Health in Iran. All cases registered in the country were included 
during 2003-2008. Incidence rates were reported based on the direct method and standard population of World 
Health Organization. The study also examined the morphology of common lung cancers. Trends in incidence 
underwent joinpoint regression analysis. Results: Based on the results of this study, 14,403 cases of lung cancer 
have been recorded of which 10,582 cases were in men and 3,821 in women. Highest incidence rates were observed 
in the 80-84 age group. Considerable variation across provinces was evident. In females squamous cell carcinoma 
(SCC) demonstrated a reduction from 24% to 16% of lesions over the period of study, while adenocarcinoma 
rose from 21% to 29%. In males a similar reduction in SCC was apparent (42% to 29%, again with increase 
in AC (13 % to 18%). Conclusions: The results show that the increase in the incidence of lung cancer the trend 
is that more men than women and in men and may be caused by changes in smoking pattern. The incidence of 
lung cancer in the North West and West provinces was higher than in other regions. 
Keywords: Incidence - Iran - lung cancer - trend - histopathology - SCC - AC.
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In females, it was the fourth most commonly diagnosed 
cancer and the second leading cause of cancer death 
(Hosseini et al., 2009). The majority of the cases now 
occur in the developing countries (55%), a large increase 
since the estimates in 1980, when it was estimated that 
only 31% of lung cancer cases occurred in developing 
countries (Parkin et al., 2005; Ferlay et al., 2010). As lung 
cancer epidemic is decreasing but in developed countries 
has growing trend (Siegel et al., 2013). In the United 
States, lung cancer is the second most common cancer 
in men and women, and it is the leading cause of cancer-
related death (Horner et al., 2009; Jiao et al., 2014). Study 
in Europe showed that most deaths due to cancer, lung 
cancer and the third most common cancer in both gender 
(Bosetti et al., 2008). Despite diagnostic and therapeutic 
improvements, the survival of lung cancer patients is still 
severe; with only 15% patients in US survive more than 
five years after diagnosis (Cruz et al., 2011). 
Lung cancer is often divided into small cell lung cancer 
(SCLC) and non-small cell lung cancer (NSCLC), (includes 
squamous cell carcinoma (SCC), adenocarcinoma (AC) 
and large cell carcinoma (LCC) (Hussain et al., 2001), 
NSCLC accounts for approximately 85% of all cases of 
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lung cancer (Molina et al., 2008).
Lung cancer was an occupational disease (Kabat, 
1996; Chan-Yeung et al., 2003; Du et al., 1996). One of the 
important risk factors for lung cancer is smoking. Smokers 
have a 20-fold increased risk of developing lung cancer 
than never-smokers, with 85%-90% of all lung cancers 
being directly linked to tobacco exposure (Hosseini et al., 
2009). Smoking accounts for 80% of the worldwide lung 
cancer burden in males and at least 50% of the burden in 
females. Smoking avoidance could almost completely 
eliminate the disease (Kazemi-Lomedasht et al., 2013). 
The World Health Organization has identified Smoking 
use as the leading global cause of preventable death, 
killing almost 6 million people every year and causing 
huge economic damage worldwide. Most of these deaths 
occur in the low- and middle-income countries and this 
disparity is expected to widen over the coming decades 
(Organization, 2011). The carcinogenesis of lung cancer 
may result from a variety of triggers, among which tobacco 
consumption was indicated to be one of the primary 
agents. While there exists a fact that never-smoking 
patients account for 15% of lung cancer patients (Hadoux 
et al., 2011). In Asian countries about 30-40% of lung 
cancers occur in never smokers, though only 10-15% of 
lung cancers occur in never smokers in Europe and North 
America (Toh and Lim, 2007). Exposure to factors such 
as occupational carcinogens, air pollution, and pollution 
from burns caused by cooking and nutrition are other risk 
factors for lung cancer (Fauci and Anthony, 2008). Age, 
gender, race, pre-existing lung disease, radon exposure, 
viral infection, environmental pollution, second-hand 
smoking and occupational exposures also are important 
contributors. In addition, direct evidence for a genetic 
predisposition to lung cancer is highlighted by several 
recent genome-wide association studies (GWAS) that 
have been done on lung cancer populations (Wang et al., 
2008; Li et al., 2010; Miki et al., 2010; Hu et al., 2011; 
Shiraishi et al., 2012). 
According to a major share lung cancer overall 
mortality from cancer and the amount of smoking 
dependence, the fact shows that lung cancer is a major 
health problem with the prognosis is generally bad for 
the world and the recognition of the status and trends of 
lung cancer and changes in recent years can be helpful in 
planning for prevention, and even predictions for supply 
necessary health care in the future, especially lung cancer. 
The aim of this study was to investigate the changes in 
the incidence of lung cancer. 
Materials and Methods
Data source
This analytic study was done based on longitudinal 
program in Iran that similar to many countries in the world 
that have national registry of cancer (NCR) is trying to 
identify all cases of cancer occurring in Iran from 2003 
to 2008. Data used in this study were obtained from a 
NCR, and Disease Control and Prevention (CDC) of 
Ministry of Health and Medical Education in Iran for 
2003-2008 (Goya, 2007). In 2008 in Iran, there are 30 
provinces and 41 Medical Universities. Deputy for the 
health of each university is responsible for health issues 
of the population and all health activities are managed 
by these deputies. All deputies for health have been 
included in the NCR. Registrar would apply the national 
registration software, which was developed by CDC. For 
pathologic centers, without software, the cancer records 
were gathered manually. The cancer office of CDC should 
provide techniques and funding supports. The data are 
transmitted every 3 months, by electronic file and also 
hard copy of “Cancer Registry Data Collection Form” 
this form is comprised of three parts: Part I, regarding 
patient’s identity characteristics in addition to the name 
of biopsy-taker physician, name of hospital, location of 
which the biopsy is taken, clinical diagnosis and date of 
biopsy sent to histological laboratory and demographic 
information of the patients includes race and residence. 
Part II includes the most important findings of patient’s 
clinical history. Part III includes preclinical findings. The 
information includes the primary location of the tumor, 
date of cancer diagnosis, morphology, and histology and 
its behavior and diagnosis method. Physicians fill the form 
of clinical data and the official personnel fill the identity 
and demographic information. Quality control has been 
coordinated in five main areas by cancer office of CDC: 
i) Regarding completeness of coverage, ii) completeness 
of details, iii) accuracy of data, iv) accuracy of reports, 
v) accuracy of interpretation, and vi) repeated cases are 
deleted from national data. Surveillance of pathology is 
based on the cancer record in several selected provinces 
to compare it with the present pathology cancer record 
for a general and complete evaluation and also for the 
accuracy of the collected data. IARC software provides a 
way to identify inaccuracies in data coding. Accordance of 
The International Classification of Diseases for Oncology 
(ICD-OC: Topography with ICD-OM: Morphology) 
is done manually and also by considering age and sex 
groups (pathology file of fatal error has been revised by 
the Scientific Society of Pathology of Iran and also by 
two masters in pathology). Method for deleting repeated 
cases: For the lack of any classified National Identification 
Numbers, the process for deleting the repeated cases 
was completed by a manual review of the record. After 
editing data of each province and considering in mind 
that for deleting of repeated cases, similar cases should 
also be the same as morphology, topography, identity, and 
Figure 1. Process of Data Collection of Cancer Cause 
in Iran
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demographic information; deletion of the repeated cases 
would be done separately in each province and finally in all 
over country by experienced manual reviewers (Figure 1). 
Statistical analysis
Crude (all ages) and age-specific rates per 100,000 
person-year for all provinces were calculated. For each 
province, the average annual age-standardized incidence 
rate (ASR) per 100,000 person-year was calculated by 
the direct method using the world standard population. 
To describe incidence time trends, we carried out 
joinpoint regression analysis using the software Joinpoint 
Regression Program, Version 4.1.1.1 October 2014. 
The analysis included logarithmic transformation 
of the rates, standard error, maximum number of one 
joinpoints, and minimum of six years between zero 
joinpoints. All other program parameters were set to 
default values. The aim of the approach is to identify 
possible joinpoints where a significant change in the 
trend occurs. In this study 0 joinpiont (Full model) was a 
significant model. The final model selected was the most 
parsimonious of these, with the estimated annual percent 
change (APC) based on the trend within each segment. 
In describing trends, the terms “significant increase” or 
“significant decrease” signify that the slope of the trend 
was statistically significant (p<0.05). All statistical tests 
were two sided.
Results 
Findings obtained from the national registry system 
of cancer showed that the incidence of lung cancer had 
increasing trend from 2003 to 2008 (Figure 1). That is, 
11,429 cases of lung cancer have been registered in the 
country. Of the incidence cases, 8463(74.05%) cases were 
male and were female 2966 (25.95%) and sex ratio (male 
to female) for disease was equal to 2.85 in these years. 
The highest incidence rate (3050cases) was observed in 
2008, but the lowest rate (963 cases) was recorded in 
2003 (Table 1).
Table 1. Frequency, CIR, and ASR-based of Sex and Year
Years Frequency (%) CIR ASR Male: Female
 Male Female Total Male Female Male Female
2003 783 281 1064 (2) 2.56 1.67 3.2 1.23 2.78
2004 1163 343 1506 (3.30) 3.35 1.04 4.38 1.51 3.39
2005 1303 484 1787 (3) 3.6 1.41 4.63 2.04 2.69
2006 1491 452 1943 (3) 4.14 1.32 5.35 1.87 3.29
2007 1512 567 2079 (3) 4.2 1.66 5.46 2.34 2.66
2008 2211 839 3050 (4) 6.14 2.46 8.04 3.55 2.63
Total 8463 2966 11429     2.86
ASR=Age-standardized incidence rate, CIR=Crude incidence rate
Table 2. Change in ASR According to Age Group and Gender from 2003-2008
Age-category 2003 2004 2005 2006 2007 2008
 Male Female Male Female Male Female Male Female Male Female Male Female
0-4 0 0.07 0 0 0 0.07 0.1 0 0 0 0 0
5-9 0 0.08 0.05 0 0.05 0 0 0 0 0 0 0
10-14 0 0.02 0.04 0.02 0 0.02 0.04 0 0 0 0.02 0
15-19 0 0.19 0.1 0.02 0.04 0.08 0.06 0.04 0 0.09 0 0.02
20-24 0.09 0.45 0.36 0.34 0.21 0.17 0.18 0.17 0.15 0.17 0.09 0.03
25-29 0.14 0.63 0.9 0.29 0.2 0.26 0.3 0.26 0.3 0.04 0.28 0.19
30-34 0.13 0.49 0.85 0.77 0.57 0.2 0.53 0.41 0.49 0.17 0.8 0.09
35-39 0.59 1.3 1.77 0.87 1.12 0.77 1.21 0.77 0.97 0.55 0.68 0.46
40-44 1.37 1.8 3.9 0.96 2.71 1.38 2.87 1.06 2.16 0.99 2.02 0.84
45-49 3.58 4.04 8.17 3.96 5.59 2.88 6.41 2.66 4.19 1.2 3.65 1.29
50-54 8.66 7.61 21.21 5.18 14.28 4.54 17.37 4.03 11.78 3.87 13.16 2.48
55-59 8.19 10.82 25.81 6.93 17.94 7.17 16.9 5.81 14.87 4.42 14.41 3.72
60-64 12.21 14.27 28.41 9.87 19.18 8.04 19.28 9.37 17.48 9.14 15.58 5.13
65-69 18.92 18.33 33.04 8.75 24.72 7.9 20.51 11.89 23.69 6.81 20.91 7.46
70-74 29.45 20.88 60.57 17.79 50.2 11.21 45.09 14.64 41.35 9.63 40.26 9.59
75-79 28.01 28.27 65.77 14.46 41.1 7.23 40.4 13.75 39.77 10.23 30.47 8.33
80-84 31.42 38.82 131.53 27.99 67.15 20.77 63 15.29 47.58 11.24 51.72 12.2
+85 14.7 28.23 59.44 12.1 25.08 6.05 15.79 7.03 14.8 4.18 12.53 3.19
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Table 3. Trend of ASR in Iranian Province from 2003 to 2008
Province 2003 2004 2005 2006 2007 2008 APC* (2003 – 2008) 
 M F M F M F M F M F M F M F
East Azarbaijan 0.3 0.07 8.27 2.19 4.05 1.36 3.21 1.2 8.22 4.48 9.32 3.81 62.21 87.53
West Azarbaijan 8.76 1.89 12.83 3.18 11.76 2.86 11.18 2.85 11.78 3.02 6.76 1.67 -4.48 -2.2
Ardabil 0.33 0 2.35 0.49 0.64 0.24 5.35 1.87 1.68 1.64 9.23 4.1 66.16 285.97^
Esfahan 1.51 0.66 1.93 1.26 3.41 2.01 3.68 0.84 2.6 1.55 4.07 2.49 18.46 21.05
Ilam 1.74 0 2.59 0.32 0.43 0 3.95 0.78 1.13 1.43 4.36 0.42 15.9 225.92
Bushehr 1.16 0 1.4 0.89 1.26 0.51 4.28 1.32 3.97 5.36 5.37 1.59 40.94^ 243.54
Tehran 6.66 3.32 2.38 0.99 2.43 1.49 4.46 1.72 4.55 2.12 10.33 5.1 14.52 13.96
Chaharmahal
  &Bakhtiari 0.2 0 0.57 1 3.26 0.82 2.97 0.43 1.86 2.17 1.65 1.64 49.21 202.06
Khorasan Razavi 3.53 2.05 4.02 2.46 2.24 1.35 5.56 1.66 4.57 2.02 4.47 2.91 7.33 3.98
Khuzestan 3.4 1.49 5.71 1.29 4.65 2.01 4.56 1.66 4.18 2.2 12.98 6.93 17.83 29.68
Zanjan 0 0 2.43 0.8 1.79 0.91 3.89 1.95 5.97 1.79 4.55 1.55 267.84 211.29
Semnan 0.22 0 0.74 0.5 1.19 0.38 2.71 0.52 1.24 0.84 1.23 6.3 92.13^ 268.10^
Sistan and 
  Baluchistan 0.38 0.39 0.65 0.66 1.21 0.51 0.79 0.49 1.67 0.85 0.08 0.38 36.55^ 23.43^
Fars 1.26 0.31 1.45 0.47 1.91 0.95 3.1 1.33 7.29 3.58 6.64 3.57 47.65^ 70.36^
Ghazvin 4.51 0.58 1.69 0.5 4.2 2.21 5.59 1.77 5.89 1.04 4.52 1.57 12.24 21.98
Qom 0 0.46 3.1 1.46 3.64 2.57 5.69 2.39 6.44 1.04 5.09 2.24 265 21.53
Golestan 1.82 0.61 1.24 1.05 1.88 0.91 3.68 0.41 4.52 2.27 2.92 1.9 21.85 22.83
Gillan 2.22 0.39 3.37 0.19 3.67 1.6 5.1 1.38 6.15 1.78 8.19 1.86 28.08^ 50.79
Lorestan 0.96 0.37 1.17 0.66 0.55 0.24 2.09 0.5 2.35 1.74 7.04 1.72 46.6 38.21
Mazandaran 2.38 0.7 3.42 1.09 5.27 1.69 3.68 1.52 3.37 1.06 7.31 2.48 16.04 19.16
Markazi 1.09 0.37 2.12 0 2.12 0.56 2.13 1.16 3.09 2.5 4.97 1.7 28.30^ 148.25
Hormozgan 0.2 0 2.68 0.31 2.92 0 2.36 0.22 1.81 0.84 3.38 0.54 76.26 212.16
Hamedan 2.07 0.66 3.22 0.32 2.58 0.54 3.07 1.07 4.14 0.75 13.96 1.97 10.14 28.24
Kurdistan 3.26 0.71 6.27 2.69 4.91 1.95 7.77 1.74 7.71 3.16 12.37 3.26 24.77^ 25.76
Kerman 3.74 0.48 5.85 1.82 4.47 1.51 3.93 2.05 5.35 2.24 7.92 3.17 10.06 34.47^
Kermanshah 5.4 1.67 4.44 0.66 2.64 0.65 2.18 1.13 6.33 2.28 7.93 2.18 16.21 17.37
Kohkilooyeh
  and Boyer Ahmad 0 0 0.49 1.06 1.28 0.51 1.36 0.95 1.99 2.17 3.66 0.56 264.75 170.8
Yazd 5.66 2.66 5.2 0.74 5.06 2.49 8.27 2.85 5.57 1.51 9.09 6.35 9.16 20.84
*Annual Percent Change; ^APC is significantly different from zero at alpha=0.05; M=Male; F=Female
Table 4. Frequency and Percent Change in the Percentage Allocated to the Morphology Data for Lung Cancer 
(2008-2003)
 2003 2004 2005 2006 2007 2008
 n (%) n (%) n (%) n (%) n (%) n (%)
Female
 Squamous Cell Carcinoma, Nos 67 (24.19) 93 (27.93) 107 (22.38) 90 (20.45) 97 (17.6) 134 (16.13)
 Adenocarcinoma, Nos 58 (20.94) 69 (20.72) 115 (24.06) 109 (24.77) 148 (26.86) 239 (28.76)
 Small Cell Carcinoma, Nos 51 (18.41) 43 (12.91) 58 (12.13) 58 (13.18) 41 (7.44) 51 (6.14)
 Carcinoma, Nos 15 (5.42) 24 (7.21) 33 (6.9) 30 (6.82) 37 (6.72) 58 (6.98)
 Bronchiolo-Alveolar Adenocarcinoma 14 (5.05) 18 (5.41) 21 (4.39) 24 (5.45) 35 (6.35) 27 (3.25)
 Non-Small Cell Carcinoma (C34._) 0 (0) 0 (0) 31 (6.49) 17 (3.86) 28 (5.08) 42 (5.05)
Male
 Squamous Cell Carcinoma , Nos 362 (41.71) 470 (40.83) 535 (41.6) 510 (34.44) 524 (34.93) 627 (28.56)
 Small Cell Carcinoma, Nos 121 (13.94) 198 (17.2) 191 (14.85) 212 (14.31) 226 (15.07) 255 (11.62)
 Adenocarcinoma, Nos 111 (12.79) 160 (13.9) 168 (13.06) 217 (14.65) 203 (13.53) 402 (18.31)
 Carcinoma, Nos 49 (5.65) 41 (3.56) 45 (3.5) 95 (6.41) 74 (4.93) 131 (5.97)
 Bronchiolo-Alveolar Adenocarcinoma 21 (2.42) 28 (2.43) 37 (2.88) 38 (2.57) 33 (2.2) 43 (1.96)
 Non-Small Cell Carcinoma (C34._) 0 (0) 0 (0) 80 (6.22) 74 (5) 99 (6.6) 107 (4.87)
The age-specific rate in men increased from 3.2 in 
2003 to 8.04 in 2008. The highest and lowest incidence 
rate in men observed in 2008 and 2003, respectively. In 
women, this rate also elevated from 1.23 in 2003 to 3.55 
in 2008 per 100,000 people. The maximum and minimum 
incidence rates were 3.55 and 1.23 per 100,000 people, 
respectively in 2008 and 2003. Furthermore, in women 
and men trend of Lung cancer incidence was increasing. 
The highest and lowest sex ratios were 3.39 and 2.63, 
respectively in 2004 and 2008 (Table 1 and Figure 1). 
Joinpoint Trend Analysis showed a significant increase 
for age-standardized incidence rate (ASR) for both sexes. 
The annual percentage change (APC) of standardized 
incidence rate for females and males were 20.5% (CI: 10.8 
to 31.1) and 16.7% (CI: 9 to 24.9), respectively.
In this study, the age-specific rate was different in age 
Asian Pacific Journal of Cancer Prevention, Vol 17, 2016 561
DOI:http://dx.doi.org/10.7314/APJCP.2016.17.2.557
Epidemiology Characteristics and Trends of Incidence of Lung Cancer in Iran, 2003-2008
of cancer cases at the beginning of the cancer registry 
program. Iranian national reports of cancer registry 
showed that the average annual percentage change for 
standardized incidence rate in all cancer was 9.6% in 
males and 10.6% in females during 2003-2008 (Goya, 
2007). Despite the increasing trend of lung cancer in 
Iran, studies carried out in America (Wahbah et al., 
2007) show the decreasing trend in the incidence of 
this cancer. In another study in Europe showed that the 
incidence of lung cancer in men in Denmark, Finland, 
Germany, Italy, Netherlands, Switzerland and the United 
Kingdom since the 1980s has decreased, but it is in other 
European countries has increased at least to the 1990s 
(Janssen-Heijnen and Coebergh, 2003). Also in the study 
between the years 2000-1983 in Hong Kong showed that 
the incidence of lung cancer in men and women in this 
country has decreased (Au et al., 2004). 
Lung cancer was an occupational disease (Du et al., 
1996; Kabat, 1996; Chan-Yeung et al., 2003) and the main 
risk factors for this disease is Smoking. The prevalence of 
smoking in men more than women (Wang et al., 1996). 
The expected incidence of this disease is higher in men 
than women. The study also it was observed that in all 
the years under study, the incidence in men than women. 
Epidemiological studies indicate that some characteristics 
of lung cancer among smokers significantly differ from 
those of unmakes. Carcinogens found in cigarettes, risk of 
developing of primary lung carcinoma increases, So that 
85% of patients with any histologic type of lung cancer, 
a history of smoking (previous or current) would have 
had. The relative risk of this cancer by smoking, about 
13 equal and in case of Long term exposure to inactive 
also increased 1.5 equal. In addition, exposure to some 
of the industrial substances, including arsenic, asbestos, 
chromium, susceptibility to chronic lung disease and 
history of previous tuberculosis with secondary scarring, 
the increased risk of primary lung carcinoma are effective 
(; Alberg, 2007; Toh, 2009).
The incidence of Lung cancer is increasing in the 
country, especially in the Northwest Territories and the 
West is increasing, therefore etiology and diagnostic 
programs in the country, especially in these areas is 
essential, And suggested that the cause of cognitive studies 
done in these areas. Our findings were obtained from the 
descriptive study on the incidence trend of the disease in 
recent years and it is recommended that analytical studies 
should be conducted to obtain a causal relationship and 
solve problems related to the disease.
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